Two recent happenings prompted this column. First, Orexigen Therapeutics drew fire from, well, nearly everyone earlier this month for an improper release of data related to its weight-loss drug Contrave. The second happening is Memorial Day weekend.
I’m assuming you, like... Read more »
Putting a number on gender inequality issues can bring attention to the scale of such matters.
During Internet Week New York, Chelsea Clinton presented data and findings from a report by the No Ceilings project, which gave a snapshot of progress... Read more »
This week’s headlines are all about second chances and new beginnings. A gene therapy company that survived on bridge loans many years ago is now one of biotech’s biggest stars. A company developing a therapy for Duchenne Muscular Dystrophy is starting... Read more »
A quick update on a plucky startup we’ve covered over the past few years: CustomMade, an online marketplace that connects craft makers and consumers, has scaled back to eight employees but is continuing operations after the majority of its staff... Read more »
From time to time, we need to step back and think about the future. What will New England’s business and innovation community look like in 10 or 20 years? Where will it fit into the national and global picture?
We can... Read more »
Sickle cell is a rare disease; a blood disorder with no effective treatments affecting around 300,000 new patients across the globe every year. While those numbers seem small compared to millions of folks with cardiovascular problems or cancer, they’re monstrous in... Read more »
Synlogic has already attracted some $35 million from investors on both coasts, including the Bill & Melinda Gates Foundation, to pursue a science fiction-like idea to make customized disease-killing bacteria. Now, the Cambridge, MA-based startup has brought in a well-known former... Read more »